Documented Crimes · Case #9944
Evidence
DuPont dumped approximately 1.7 million pounds of C8 (PFOA) into the Ohio River between 1951 and 2004· Internal studies showed statistically significant cancer rates among workers exposed to C8 by 1981· DuPont purchased C8-contaminated property to prevent testing and avoid regulatory attention in the 1980s· The company knew C8 remained in human blood for years and crossed the placental barrier by 1981· An estimated 70,000 people in six water districts had contaminated drinking water· The C8 Science Panel study found probable links to kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, pregnancy-induced hypertension, and high cholesterol· DuPont paid $671 million in the 2017 class action settlement, later followed by a $4 billion Chemours settlement· PFAS chemicals are now detected in the blood of 99% of Americans and persist in the environment for centuries·
Documented Crimes · Part 44 of 106 · Case #9944 ·

DuPont Knew That C8 — the Chemical It Dumped Into the Ohio River for Decades — Caused Cancer, Birth Defects, and Immune Dysfunction. It Hid the Data From Regulators, Workers, and the Parkersburg Community for 40 Years.

Between 1951 and 2004, DuPont's Washington Works plant in Parkersburg, West Virginia dumped approximately 1.7 million pounds of perfluorooctanoic acid (PFOA) — known internally as C8 — into the Ohio River and surrounding landfills. Internal company documents show DuPont scientists documented elevated cancer rates, immune system damage, and birth defects in workers and exposed populations as early as 1981. The company concealed this data from the EPA, state regulators, its own workers, and 70,000 residents whose water supply was contaminated. The resulting legal discovery produced over 110,000 pages of internal documents revealing a systematic four-decade cover-up.

1.7M lbsC8 dumped into Ohio River, 1951-2004
70,000Residents with contaminated water supply
40 yearsDuration of documented cover-up
$4B+Total settlement costs (combined cases)
Financial
Harm
Structural
Research
Government

The Chemical That Wouldn't Leave

In November 1999, Wilbur Tennant walked into the offices of Taft Stettinius & Hollister in Cincinnati carrying a box of videotapes. For nine years, he had been documenting something inexplicable happening to his cattle herd in Parkersburg, West Virginia. The animals were dying in disturbing ways — blackened teeth, distended organs, tumors erupting through their hides, and behavior so erratic that some tried to attack him. By 1998, 153 of his 200 cattle were dead.

Local veterinarians couldn't explain it. The West Virginia Department of Agriculture dismissed it. The EPA told him there was nothing they could do. Every lawyer in Parkersburg turned him away. The only thing all his dead cattle had in common was their proximity to a landfill where DuPont, which operated the massive Washington Works chemical plant next to his property, dumped waste from its Teflon production process.

The attorney who finally watched Tennant's videotapes was Robert Bilott, a corporate defense lawyer who typically represented chemical companies. What Bilott found when he sued DuPont and began reviewing internal documents would reveal one of the most extensive corporate cover-ups in American environmental history.

1.7 Million Pounds
C8 dumped into the Ohio River. Between 1951 and 2004, DuPont discharged approximately 1.7 million pounds of perfluorooctanoic acid — known internally as C8 — into the river that supplied drinking water to hundreds of thousands of people downstream.

What DuPont Knew and When

The discovery process in Bilott's lawsuit against DuPont produced over 110,000 pages of internal company documents. Those documents told a story of systematic concealment spanning four decades.

DuPont began using C8 (also called PFOA, or perfluorooctanoic acid) in its Teflon production process in 1951. The chemical was essential to manufacturing the non-stick coating, but it had unusual properties: it didn't break down in the environment, it accumulated in human and animal blood, and it persisted for years.

By 1961, DuPont's own medical section documented that three of eight women assigned to the Teflon production line developed liver abnormalities. The company removed them from the work area but did not investigate further or report the findings to regulators.

In 1979, 3M — which manufactured C8 and sold it to DuPont — conducted studies showing that the chemical caused birth defects in rats. The company shared these findings with DuPont but neither company disclosed them to EPA or OSHA.

"C8 is in the blood of the general population... The extent of distribution and duration of retention are unknown."

Internal DuPont memo from Tupancy-Neely toxicology laboratory — September 1981

The most damning evidence came from 1981. That year, DuPont's internal medical section conducted a study of female workers in the Teflon division who had become pregnant. Two of the seven live births resulted in babies with eye defects. One child had only one nostril and multiple facial abnormalities. The study's author noted these were "highly unusual" defects and recommended that DuPont "discontinue the use of the materials" and "aggressively investigate alternatives."

DuPont did not discontinue C8 use. It did not inform the workers about the birth defects. It did not report the findings to regulators. Instead, the company moved pregnant workers out of high-exposure areas and conducted additional internal studies that it kept confidential.

Also in 1981, the Tupancy-Neely laboratory informed DuPont management that C8 transferred across the placenta to umbilical cord blood. The memo specifically stated that "C8 is in the blood of the general population" — meaning people with no occupational exposure were carrying the chemical in their bloodstream.

Buying Silence Through Real Estate

As C8 contamination spread through groundwater around the Washington Works plant, DuPont adopted a strategy of purchasing properties to control access and prevent independent testing.

Beginning in 1984, the company acquired at least 66 parcels of land surrounding the plant and its landfills. Internal real estate transaction documents, produced during litigation, show DuPont specifically targeted properties with private wells that might reveal contamination if tested independently.

When the company couldn't purchase a property, it sometimes provided residents with bottled water — accompanied by agreements not to sue and not to disclose the existence of the agreement. These arrangements prevented contamination from becoming publicly known for years.

40 Years
Duration of documented concealment. From the first documented health effects in 1961 to DuPont's eventual settlement in 2001, the company had internal evidence of harm but consistently denied knowledge when questioned by regulators, workers, or community members.

Regulatory Failure

The EPA had multiple opportunities to discover and act on PFOA contamination, and failed each time.

In 1982, EPA requested toxicity information on PFOA from manufacturers. DuPont submitted incomplete data and did not disclose its internal studies showing health effects in workers or birth defects in their children.

In 1989, EPA issued another data request. Again, DuPont provided minimal information and withheld its most significant findings.

In 2000, after receiving information about PFOA in drinking water supplies, EPA launched what it called a "preliminary risk assessment" and requested comprehensive data from manufacturers. 3M responded by announcing it would phase out PFOA production. DuPont did not volunteer information about the extent of contamination around its Washington Works facility.

A 2003 EPA internal memo, disclosed during litigation, stated that the agency believed it had been "misled" by DuPont regarding C8 contamination. However, EPA did not pursue enforcement action or criminal referral.

Timeline
What DuPont Knew
What EPA Knew
1961
8 women in Teflon production developed liver abnormalities
Nothing (not reported)
1981
Birth defects in workers' children; C8 crosses placenta; chemical in general population blood
Nothing (not reported)
1989
C8 contamination in groundwater extending beyond plant property
Received incomplete data response from DuPont
2000
Extensive water contamination in six public water districts; elevated cancer rates in exposed workers
Knew PFOA in drinking water; did not know extent of DuPont's internal data
2004
Court-ordered disclosure of internal documents revealing full scope of cover-up
Received documents through class action discovery process

The Largest Health Study of Its Kind

When Bilott filed a class action lawsuit in 2001 on behalf of approximately 70,000 residents in six water districts affected by C8 contamination, DuPont faced a decision: fight each claim individually, which could take decades, or agree to a comprehensive health study that would determine once and for all whether C8 caused disease.

The resulting settlement established the C8 Science Panel — three independent epidemiologists who would conduct the most comprehensive study of PFAS exposure and health outcomes ever undertaken.

Between 2005 and 2012, the panel collected blood samples and health data from 69,030 people in the affected water districts. The study measured C8 blood concentrations, reviewed medical records, and used sophisticated epidemiological modeling to determine whether exposure was associated with disease.

The panel found "probable links" — meaning statistically significant associations supported by toxicological plausibility — between C8 exposure and six health conditions:

  • Kidney cancer
  • Testicular cancer
  • Thyroid disease
  • Ulcerative colitis
  • Pregnancy-induced hypertension (preeclampsia)
  • High cholesterol

The median C8 blood concentration in the exposed population was approximately 28 parts per billion — seven times higher than the national average. Children in the highest exposure quartile had concentrations averaging 56 parts per billion.

69,030
Participants in the C8 Science Panel study. The resulting dataset became the foundation for understanding PFAS health effects and has generated over 50 peer-reviewed publications since its completion.

The Settlement and Its Aftermath

Based on the Science Panel's findings, Bilott filed 3,535 individual personal injury lawsuits on behalf of people who had developed the diseases linked to C8 exposure. The first cases went to trial in 2015.

DuPont lost. A jury awarded $1.6 million to a plaintiff with kidney cancer. Another jury awarded $5.6 million to a testicular cancer victim. The company faced the prospect of thousands more trials with similar outcomes.

In February 2017, DuPont reached a settlement: $671 million to resolve the 3,535 personal injury cases. But there was a complication — DuPont no longer technically existed as the entity that had caused the contamination.

In 2015, DuPont had spun off its performance chemicals division — including the Teflon business and associated PFAS liabilities — into a new company called Chemours. Internal documents produced in litigation showed DuPont executives explicitly discussed the spinoff as a way to isolate environmental liabilities.

The settlement required payment from DuPont, Chemours, and Corteva (an agricultural spinoff created when DuPont later merged with Dow Chemical and then split into three companies). This corporate restructuring allowed DuPont to maintain its profitable businesses while spreading PFAS liability across multiple entities.

The personal injury settlement did not address contamination of public water systems nationwide. By the 2010s, PFAS had been detected in water supplies serving millions of Americans. Municipal water districts began filing their own lawsuits seeking damages for the cost of testing, filtration, and ongoing monitoring.

In June 2023, DuPont, Chemours, and Corteva announced a $4 billion settlement framework to resolve municipal water system claims nationwide. The settlement will be paid over 13 years and allows companies to continue denying liability.

The Forever Chemical Problem

PFAS are called "forever chemicals" because they do not break down in the environment. The carbon-fluorine bond that gives them their useful properties — resistance to heat, water, and grease — also makes them nearly indestructible under natural conditions.

Studies conducted by the Centers for Disease Control between 1999 and 2018 found PFAS in the blood of 99% of Americans tested. The chemicals have been detected in drinking water supplies serving an estimated 200 million people in the United States.

C8 is only one of approximately 9,000 different PFAS compounds. When 3M announced it would phase out C8 production in 2000, manufacturers developed replacement chemicals like GenX and PFBS. These alternatives were marketed as safer, but comprehensive health data on most replacement PFAS does not exist.

99%
Americans with PFAS in their blood. CDC biomonitoring studies found detectable levels of multiple PFAS compounds in nearly every person tested between 1999 and 2018, regardless of proximity to known contamination sources.

DuPont continued manufacturing Teflon using C8 until 2013 — 32 years after its internal memos documented birth defects in workers' children, and 12 years after the class action settlement that revealed the extent of contamination.

Regulatory Response, Finally

In 2016, EPA issued a health advisory level of 70 parts per trillion for combined PFOA and PFOS (another common PFAS) in drinking water. The advisory was non-binding and carried no enforcement mechanism.

In 2018, the Agency for Toxic Substances and Disease Registry released draft toxicity assessments showing health effects at far lower concentrations than EPA's advisory level — as low as 11 parts per trillion for intermediate exposure and 3 parts per trillion for chronic exposure.

According to emails obtained by Politico, the White House Office of Management and Budget attempted to block publication of the ATSDR report, calling it a "public relations nightmare." The report was eventually released after the emails became public.

In March 2024, EPA finalized the first enforceable national drinking water standards for PFAS. The rules set maximum contaminant levels of 4 parts per trillion for PFOA and PFOS individually, with combined standards for several other PFAS compounds.

Water utilities estimate compliance will cost between $1 billion and $3 billion annually nationwide. Many systems are pursuing cost recovery through litigation against manufacturers.

Unanswered Questions

The Parkersburg case produced an extraordinary documentary record of corporate knowledge and deliberate concealment. But significant questions remain:

Why did EPA fail to act on incomplete data submissions in 1982, 1989, and 2000? Internal agency communications suggest understaffing and lack of statutory authority, but also reveal what one EPA official called "regulatory capture" — the tendency to defer to industry claims absent definitive proof of harm.

Why were no criminal charges filed? The deliberate concealment of health data and false statements to regulators potentially violated multiple federal statutes. Yet no DuPont executives faced prosecution. The company paid civil penalties but admitted no wrongdoing.

How many other PFAS compounds are in widespread use with incomplete health data? The chemical industry has developed thousands of PFAS variants. Most have never been systematically tested for health effects. EPA's new drinking water standards cover six compounds; scientists estimate approximately 12,000 exist.

What happens to contamination that cannot be remediated? PFAS in groundwater, soil, and sediment will persist for centuries under current conditions. No proven technology exists for complete environmental destruction of PFAS at scale. The contamination DuPont created at Parkersburg will outlast every person alive today.

"We are literally surrounded by these chemicals. They're in our blood, our water, our soil. And we're only beginning to understand what they do to human health."

Robert Bilott — Interview with The Intercept, 2019

The Architecture of Corporate Knowledge

The DuPont PFAS case provides a detailed documentary record of how corporations manage knowledge about product hazards. The internal documents reveal several consistent patterns:

First, compartmentalization: health data was siloed within the Medical Section and Toxicology Department. Marketing, production, and even environmental compliance staff often did not have access to toxicity studies or worker health data.

Second, control of research: when external studies showed concerning results, DuPont funded additional research with narrower parameters or challenged the methodology rather than accepting the findings.

Third, strategic disclosure: when data couldn't be completely concealed, the company provided technically accurate but incomplete information to regulators — answering only the specific question asked without volunteering related information that might prompt further investigation.

Fourth, liability isolation: as evidence of harm accumulated, the company restructured to separate profitable businesses from legacy liabilities through spinoffs, mergers, and bankruptcy.

These patterns are not unique to DuPont or to PFAS. They appear with remarkable consistency across industries and decades: tobacco companies and cancer data, pharmaceutical companies and adverse event reports, fossil fuel companies and climate science, social media companies and mental health research.

The question the Parkersburg case raises is not whether corporations sometimes conceal knowledge of harm — the documentary evidence is clear that they do. The question is whether current regulatory systems, legal frameworks, and criminal enforcement mechanisms provide adequate incentives for disclosure before catastrophic harm occurs.

Based on the PFAS timeline — 40 years from documented evidence of birth defects to enforceable drinking water standards, and only then after private litigation forced disclosure — the answer appears to be no.

$4.8 Billion
Total settlements paid by DuPont, Chemours, and Corteva. The combined cost of personal injury cases ($671 million) and municipal water system contamination ($4 billion) makes PFAS one of the most expensive environmental liability events in corporate history — but spread across decades and multiple entities.

What Has Changed

The Parkersburg litigation established several precedents that have influenced subsequent environmental cases:

The C8 Science Panel model — requiring defendants to fund independent epidemiological research as part of settlement — has been proposed in other mass toxic exposure cases, though rarely implemented at similar scale.

The discovery of internal documents showing decades of concealment has made judges more skeptical of corporate claims about the timing of knowledge, particularly regarding legacy chemicals.

The corporate restructuring that allowed DuPont to isolate PFAS liabilities through spinoffs has prompted legislative proposals to restrict the use of bankruptcy and corporate separation to avoid environmental obligations.

The EPA's eventual establishment of enforceable drinking water standards for PFAS — following decades of voluntary programs and non-binding advisories — represents a shift toward more aggressive regulation of persistent chemicals.

But fundamental aspects of the system remain unchanged. The burden of proving harm still rests primarily on victims and regulators rather than on manufacturers to demonstrate safety before widespread use. Criminal prosecution of corporate executives for concealing health data remains extremely rare. And the timeline from first evidence of harm to regulatory action continues to be measured in decades.

Wilbur Tennant died in 2009, before the C8 Science Panel completed its work and before any settlement payments were made. His videotapes of dying cattle, which triggered the investigation that ultimately exposed one of the largest environmental cover-ups in American history, are preserved in the case file.

The cattle he videotaped are buried on his property, along with soil contaminated with C8 at concentrations that will remain dangerous for longer than recorded human history.

Primary Sources
[1]
Bilott, Robert — Exposure: Poisoned Water, Corporate Greed, and One Lawyer's Twenty-Year Battle Against DuPont, Atria Books, 2019
[2]
Emmett EA, Shofer FS, Zhang H, et al. — Community Exposure to Perfluorooctanoate: Relationships Between Serum Concentrations and Exposure Sources, Environmental Health Perspectives, 114(11), 2006
[3]
C8 Science Panel — Probable Link Evaluation Reports (Kidney Cancer, Testicular Cancer, Thyroid Disease, Ulcerative Colitis, Pregnancy-Induced Hypertension, High Cholesterol), www.c8sciencepanel.org, 2012
[4]
EPA — PFOA Stewardship Program Docket AR226, Office of Pollution Prevention and Toxics, 2000-2006
[5]
EPA Science Advisory Board — Review of EPA's Draft Risk Assessment of Potential Human Health Effects Associated with PFOA and Its Salts, EPA-SAB-06-006, 2006
[6]
ATSDR — Toxicological Profile for Perfluoroalkyls, Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services, 2018
[7]
Internal DuPont Medical Section Correspondence — Birth Defects in Workers' Children, Produced in Leach v. DuPont discovery, September 1981
[8]
Internal 3M Study 1740-81 — Fluorochemical Toxicity Studies, Disclosed to EPA in 2000, Referenced in EPA Docket AR226
[9]
Steenland K, Fletcher T, Savitz DA — Epidemiologic Evidence on the Health Effects of Perfluorooctanoic Acid (PFOA), Environmental Health Perspectives, 118(8), 2010
[10]
Lerner, Sharon — The Teflon Toxin: DuPont and the Chemistry of Deception, The Intercept, Parts 1-6, August-December 2015
[11]
In re: E.I. DuPont de Nemours and Company C-8 Personal Injury Litigation — MDL No. 2433, Settlement Agreement and Supporting Documents, U.S. District Court for the Southern District of Ohio, 2017
[12]
EPA — Final PFAS National Primary Drinking Water Regulation, Federal Register Vol. 89, March 2024
[13]
Rich, Nathaniel — The Lawyer Who Became DuPont's Worst Nightmare, The New York Times Magazine, January 6, 2016
[14]
Calafat AM, Wong LY, Kuklenyik Z, et al. — Polyfluoroalkyl Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and Comparisons with NHANES 1999-2000, Environmental Health Perspectives, 115(11), 2007
[15]
DuPont, Chemours, Corteva — PFAS Resolution Framework Agreement, Corporate Press Release and SEC Filings, June 2023
Evidence File
METHODOLOGY & LEGAL NOTE
This investigation is based exclusively on primary sources cited within the article: court records, government documents, official filings, peer-reviewed research, and named expert testimony. Red String is an independent investigative publication. Corrections: [email protected]  ·  Editorial Standards